Loading [MathJax]/jax/output/SVG/jax.js
Research article

A methylomics-correlated nomogram predicts the recurrence free survival risk of kidney renal clear cell carcinoma


  • Received: 04 August 2021 Accepted: 10 September 2021 Published: 08 October 2021
  • Background 

    Various studies have suggested that the DNA methylation signatures were promising to identify novel hallmarks for predicting prognosis of cancer. However, few studies have explored the capacity of DNA methylation for prognostic prediction in patients with kidney renal clear cell carcinoma (KIRC). It's very promising to develop a methylomics-related signature for predicting prognosis of KIRC.

    Methods 

    The 282 patients with complete DNA methylation data and corresponding clinical information were selected to construct the prognostic model. The 282 patients were grouped into a training set (70%, n = 198 samples) to determine a prognostic predictor by univariate Cox proportional hazard analysis, least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analysis. The internal validation set (30%, n = 84) and an external validation set (E-MTAB-3274) were used to validate the predictive value of the predictor by receiver operating characteristic (ROC) analysis and Kaplan–Meier survival analysis.

    Results 

    We successfully identified a 9-DNA methylation signature for recurrence free survival (RFS) of KIRC patients. We proved the strong robustness of the 9-DNA methylation signature for predicting RFS through ROC analysis (AUC at 1, 3, 5 years in internal dataset (0.859, 0.840, 0.817, respectively), external validation dataset (0.674, 0.739, 0.793, respectively), entire TCGA dataset (0.834, 0.862, 0.842, respectively)). In addition, a nomogram combining methylation risk score with the conventional clinic-related covariates was constructed to improve the prognostic predicted ability for KIRC patients. The result implied a good performance of the nomogram.

    Conclusions 

    we successfully identified a DNA methylation-associated nomogram, which was helpful in improving the prognostic predictive ability of KIRC patients.

    Citation: Xiuxian Zhu, Xianxiong Ma, Chuanqing Wu. A methylomics-correlated nomogram predicts the recurrence free survival risk of kidney renal clear cell carcinoma[J]. Mathematical Biosciences and Engineering, 2021, 18(6): 8559-8576. doi: 10.3934/mbe.2021424

    Related Papers:

    [1] Abigail Gbemisola Adeyonu, Olubunmi Lawrence Balogun, Babatunde Oluseyi Ajiboye, Isaac Busayo Oluwatayo, Abiodun Olanrewaju Otunaiya . Sweet potato production efficiency in Nigeria: Application of data envelopment analysis. AIMS Agriculture and Food, 2019, 4(3): 672-684. doi: 10.3934/agrfood.2019.3.672
    [2] Saeed Hosseini Nejad, Reza Moghaddasi, Amir Mohammadi Nejad . On the role of credit in agricultural growth: An Iranian panel data analysis. AIMS Agriculture and Food, 2018, 3(1): 1-11. doi: 10.3934/agrfood.2018.1.1
    [3] Lindie V. Maltitz, Yonas T. Bahta . Empowerment of smallholder female livestock farmers and its potential impacts to their resilience to agricultural drought. AIMS Agriculture and Food, 2021, 6(2): 603-630. doi: 10.3934/agrfood.2021036
    [4] Ogunniyi Adebayo, Omonona Bolarin, Abioye Oyewale, Olagunju Kehinde . Impact of irrigation technology use on crop yield, crop income and household food security in Nigeria: A treatment effect approach. AIMS Agriculture and Food, 2018, 3(2): 154-171. doi: 10.3934/agrfood.2018.2.154
    [5] Raulston Derrick Gillette, Norio Sakai, Godfrid Erasme Ibikoule . Role and impact of contract farming under various pricing standards: A case of Guyana's rice sector. AIMS Agriculture and Food, 2024, 9(1): 336-355. doi: 10.3934/agrfood.2024020
    [6] Hien Thi Vu, Ke-Chung Peng, Rebecca H. Chung . Efficiency measurement of edible canna production in Vietnam. AIMS Agriculture and Food, 2020, 5(3): 466-479. doi: 10.3934/agrfood.2020.3.466
    [7] Abbas Ali Chandio, Yuansheng Jiang . Factors influencing the adoption of improved wheat varieties by rural households in Sindh, Pakistan. AIMS Agriculture and Food, 2018, 3(3): 216-228. doi: 10.3934/agrfood.2018.3.216
    [8] Marcello Mastrorilli, Raffaella Zucaro . Towards sustainable use of water in rainfed and irrigated cropping systems: review of some technical and policy issues. AIMS Agriculture and Food, 2016, 1(3): 294-314. doi: 10.3934/agrfood.2016.3.294
    [9] Radhwane Derraz, Farrah Melissa Muharam, Noraini Ahmad Jaafar . Uncertainty sources affecting operational efficiency of ML algorithms in UAV-based precision agriculture: A 2013–2020 systematic review. AIMS Agriculture and Food, 2023, 8(2): 687-719. doi: 10.3934/agrfood.2023038
    [10] Boris Boincean, Amir Kassam, Gottlieb Basch, Don Reicosky, Emilio Gonzalez, Tony Reynolds, Marina Ilusca, Marin Cebotari, Grigore Rusnac, Vadim Cuzeac, Lidia Bulat, Dorian Pasat, Stanislav Stadnic, Sergiu Gavrilas, Ion Boaghii . Towards Conservation Agriculture systems in Moldova. AIMS Agriculture and Food, 2016, 1(4): 369-386. doi: 10.3934/agrfood.2016.4.369
  • Background 

    Various studies have suggested that the DNA methylation signatures were promising to identify novel hallmarks for predicting prognosis of cancer. However, few studies have explored the capacity of DNA methylation for prognostic prediction in patients with kidney renal clear cell carcinoma (KIRC). It's very promising to develop a methylomics-related signature for predicting prognosis of KIRC.

    Methods 

    The 282 patients with complete DNA methylation data and corresponding clinical information were selected to construct the prognostic model. The 282 patients were grouped into a training set (70%, n = 198 samples) to determine a prognostic predictor by univariate Cox proportional hazard analysis, least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analysis. The internal validation set (30%, n = 84) and an external validation set (E-MTAB-3274) were used to validate the predictive value of the predictor by receiver operating characteristic (ROC) analysis and Kaplan–Meier survival analysis.

    Results 

    We successfully identified a 9-DNA methylation signature for recurrence free survival (RFS) of KIRC patients. We proved the strong robustness of the 9-DNA methylation signature for predicting RFS through ROC analysis (AUC at 1, 3, 5 years in internal dataset (0.859, 0.840, 0.817, respectively), external validation dataset (0.674, 0.739, 0.793, respectively), entire TCGA dataset (0.834, 0.862, 0.842, respectively)). In addition, a nomogram combining methylation risk score with the conventional clinic-related covariates was constructed to improve the prognostic predicted ability for KIRC patients. The result implied a good performance of the nomogram.

    Conclusions 

    we successfully identified a DNA methylation-associated nomogram, which was helpful in improving the prognostic predictive ability of KIRC patients.



    As history indicated, infectious diseases have been becoming a main enemy affecting human's health and economic development. Mathematical modelling is an useful tool to investigate the mechanisms of transmission of diseases and make optimal control measures [1]. There are many ways to suppress the disease transmission, such as media propagation, vaccination, quarantine and so on [2]. As we know, vaccination is one of effective methods to control and prevent disease prevalence. Indeed, vaccination has succeeded in slowing down transmission of diseases such as tuberculosis, hepatitis, and some children diseases [3]. However, it has been reported that vaccination immunity waning has caused some diseases reemergence such as measles, rubella and pertussis. There is no doubt that vaccine waning has great effects on understanding the evolution of diseases. Based on the epidemic compartment knowledge in Kermack and McKendrick [4,5,6], an SIVS epidemic model can be written as follows [7]:

    dS(t)dt=bβSI(μ+p)S+ϵV,dI(t)dt=βSI(μ+γ)I,dR(t)dt=γI(t)μR,dV(t)dt=pS(μ+ϵ)V(t), (1)

    where the total population is splited into four classes (Susceptible, Infected, Recovered and Vaccinated). b is the birth rate, μ is the natural death rate, β is the transmission rate, γ is the recovery rate, p is the vaccinated rate, ϵ is the vaccine waning rate. In [7], Li and Yang investigated two vaccine strategies consisting of continuous and impulsive styles, and they obtained the global stability of equilibria by constructing Lyapunov functionals. Zaleta and Hernández proposed an SIVS model with a standard incidence rate and a disease-induced death rate [8]. They showed that their model exhibits a backward bifurcation. Based on model (1), many researchers have evolved many different structures and successfully captured the key characters of diseases transmission and evaluated the risk of their prevalence (see, for examples, [9,10,11]).

    We note that all models mentioned above are based on the homogeneous assumptions for host population. However, host heterogeneity plays an important role in exploring their dynamics. Many diseases such as tuberculosis, hepatitis C, HIV/AIDS and so on infect their host for a long time and sometimes for the duration of lifespan. During the long infectious period, the variability of infectivity with age-since-infection has been studied most extensively in HIV infection [12]. The immunity waning process of pertussis satisfies Gamma distributions [13], which can be expressed by the vaccinated age. In this case, the densities of the infected and vaccinated in time t and age a are denoted by i(t,a), and v(t,a), respectively. The parameters β,γ, and ϵ in system (1) are associated with age a. Based on system (1), the model can be described as follows:

    dS(t)dt=bS(t)0β(a)i(t,a)da(μ+p)S(t)+0ϵ(a)v(t,a)da,i(t,a)t+i(t,a)a=(μ+γ(a))i(t,a),v(t,a)t+v(t,a)a=(μ+ϵ(a))v(t,a),i(t,0)=S(t)0β(a)i(t,a)da,v(t,0)=pS(t),dR(t)dt=0γ(a)i(t,a)daμR(t),S(0)=S0R+,i(0,a)=i0(a)L1+(R+),v(0,a)=v0(a)L1+(R+), (2)

    where R+=(0,+), and L1+(R+) denotes the space of all the integral functions in L1 and maintaining positivity after integral. Obviously, system (2) is a hybrid system combining an ordinary differential equation and two partial differential equations. Global dynamics of such a system has been becoming a challenging issue due to lack of well posed mathematical techniques.

    On the other hand, some diseases such as mumps, measles, gonorrhea, HIV/AIDS etc exhibit heterogeneity in host populations. Groups can be geographical such as counties, cities, communities, or epidemiological as different infectivity and multi-stain agents. Many authors introduced an irreducible matrix and summing elements of the matrix together as a kernel function to describe the inter-group and intra-group infections. In [14], Lajmanovich and Yorke proposed the earliest multi-group model for gonorrhea spread in a community and investigated the global stability. They assumed that the total size of population doesn't change and maintain a constant. Under this assumption their model can be simplified to just consider the infected classes. Since then, many multi-group epidemic models have been studied (see, for example [15,19,20]). In [21], Guo et al proposed a multi-group SIR epidemic model and used the graph-theoretic approach to investigate the global stability of endemic equilibrium. This method combining with nonnegative irreducible matrix is an effective tool in solving the global behavior of endemic equilibrium. In [20], Kuniya considered a multi-group SVIR model to explore the global behavior of equilibria by constructing Lyapunov functional and using a developed graph-theoretic method. There are few literatures incorporating age structure into multi-group epidemic models [15].

    Motivated by the discussions above, we separate the total population into n groups and four compartments: susceptible, infected, and vaccinated, recovered, denoted by Sk(t),ik(t,a) and vk(t,a) and Rk(t), respectively. ik(t,a) denotes the infected individuals at time t and infection age a in group k. vk(t,a) denotes the vaccinated individuals at time t and vaccinated age a in group k. Rk(t) represents the recovered individuals at time t. Susceptible individuals in group k can be infected by infected individuals in group j at rate βkj(a). Hence, we denote the incidence rate in group k in the form of

    λk(t)=nj=10βkj(a)ij(t,a)da.

    Susceptible individuals in group k can be vaccinated at rate pk and become vaccinated individuals with immunity. The vaccinated individuals in group k lose its immunity at rate ϵk(a) and become susceptible individuals. A multi-group SIRVS epidemic model is formulated by the following differential equations:

    dSk(t)dt=bkSk(t)λk(t)(μk+pk)Sk(t)+0ϵk(a)vk(t,a)da,ik(t,a)t+ik(t,a)a=(μk+γk(a))ik(t,a),vk(t,a)t+vk(t,a)a=(μk+ϵk(a))vk(t,a),ik(t,0)=Sk(t)λk(t),vk(t,0)=pkSk(t),dRk(t)dt=0γk(a)ik(t,a)daμkRk(t), (3)

    where bk denotes the birth rate, γk is the recovery rate with respect to infection age a, μk is the natural death rate in group k. In order to satisfy the biological meaning, all the parameters are assumed to be nonnegative and bk>0 and μk>0. Note that the total population Nk(t)=Sk(t)+0ik(t,a)da+Rk(t)+0vk(t,a)da satisfies the following equation:

    dNk(t)dt=bkμkNk(t), (4)

    which yields limtNk(t)=bkμk. Without loss of generality, we assume that the total population is Nk=bkμk. Since the first four equations in (3) do not contain the variable Rk, we can consider the following closed subsystem:

    dSk(t)dt=bkSk(t)λk(t)(μk+pk)Sk(t)+0ϵk(a)vk(t,a)da,ik(t,a)t+ik(t,a)a=(μk+γk(a))ik(t,a),vk(t,a)t+vk(t,a)a=(μk+ϵk(a))vk(t,a),ik(t,0)=Sk(t)λk(t),vk(t,0)=pkSk(t),Sk(0)=Sk0R+,ik(0,a)=ik0(a)L1+(R+),vk(0,a)=vk0(a)L1+(R+). (5)

    Once behaviors of Sk(t), ik(t,a) and vk(t,a) are known, those of Rk(t) can be derived from the fourth equation in (3). For convenience, we make the following assumption:

    Assumption 1.1. For system (5), we assume

    (ⅰ) For each j,k{1,2,,n}, βjk(a),γk(a),ϵk(a)L+(0,). That is, there exist positive constants β+jk and ϵ+k such that

    esssupa[0,+)βjk(a)=β+jk,esssupa[0,)γk(a)=γ+k,esssupa[0,)ϵk(a)=ϵ+k.

    (ⅱ) For each j,k{1,2,,n}, βjk(a) satisfies the following property:

    limh00|βjk(a+h)βjk(a)|da=0.

    (ⅲ) For each j,k{1,2,,n}, there exists an ε0>0 such that for almost all a[0,+),βjk(a)ε0.

    (ⅳ) For each j,k{1,2,,n}, the matrix (βjk)n×n is irreducible.

    The assumptions above on the parameters in system (5) are naturally satisfied for some real diseases. Evidence exists that the infectivity βjk(a) has been addressed by Gamma and Log-normal distributions for smallpox [16,17], Weibull distribution for Ebola [18]. It is easy to find that all of these probability distribution functions have peak values and they are continuous. Hence, (ⅰ) and (ⅱ) in Assumption 1.1 readily hold. As for (ⅲ) in Assumption 1.1, we can modify it in a more generalized form:

    (ⅲ)' There exists a positive constant}aβ such that βjk(a)(k,jN) is positive in a neighbourhood of aβ.

    Obviously, the distribution functions mentioned above have this property. If we assume that every group keeps up close exchanges in mutual contact, then the generated graph is strongly connected. (ⅳ) in Assumption 1.1 is satisfied automatically.

    In order to investigate the dynamic behavior of system (5), define the functional spaces

    X=(R×L1(R+,R))n,Y=X×X,Z=Rn×X×X,

    and

    X0=({0}×L1(R+,R))n,Y0=X0×X0,Z0=Rn×X0×X0

    with the norm

    ϕRn=nj=1|ϕj|,ϕ=(ϕ1,ϕ2,,ϕn)TRn,
    ϕX0=nj=10|ϕj(a)|da,ϕ=(ϕ1,ϕ2,,ϕn)TL1(R+,Rn),
    ψY0=ψ1X0+ψ2X0,ψZ=ψ1Rn+ψ2X0+ψ3X0,

    where ψi=(ψi1,ψi2,,ψin)TRn or L1(R+,Rn)(i=1,2,3). In addition, denote X+,Y+ and Z+ as the positive cones of X,Y and Z. We define

    X0+=X0X+,Y0+=Y0Y+,Z0+=Z0Z+.

    Under Assumption 1.1 we see that the set

    Ω={(S(t),0,i(t,),0,v(t,))Z0+|Sk(t)+0ik(t,a)da+0vk(t,a)dabkμk}

    is invariant, where S=(S1,S2,,Sn)T, i=(i1,i2,,in)T and v=(v1,v2,,vn)T. In the following, we just assume that all the initial values are taken from Ω.

    Next, we will show that system (5) has a globally classic solution in Ω. Let b,p,μ,γ(a), and ϵ(a) be diagonal matrixes given by

    b=diag(b1,b2,,bn),p=diag(p1,p2,,pn),μ=diag(μ1,μ2,,μn),γ(a)=diag(γ1(a),γ2(a),,γn(a)),ϵ(a)=diag(ϵ1(a),ϵ2(a),,ϵn(a)). (6)

    Then let us define a linear operator Ai:D(Ai)XX as

    Ai(0ψ)=(0Aiψ)=(0ddaψ(μ+γ(a))ψ),

    and

    Av(0ψ)=(0Avψ)=(0ddaψ(μ+ϵ(a))ψ),

    where D(Aj)={(0,ψ)X0|ψ is obsolutely continuous,ψL1(R+,Rn),ψ(0)=0}, j=i,v. If λρ(Ai) (ρ(Ai) denotes the resolvent set of Ai), for any initial value (θi,ϕi)TX, we have

    ψi(a)=ea0[μi+γi(s)+λ]dsθi+a0ϕi(s)eas[μi+γi(ξ)+λ]dξds. (7)

    Similarly, for any λρ(Av) and any initial value (θv,ϕv)TX, we have

    ψv(a)=ea0[μi+ϵi(s)+λ]dsθv+a0ϕi(s)eas[μi+ϵi(ξ)+λi]dξds. (8)

    Furthermore, define two nonlinear operators as

    Fj(0ψ)=(Bj(ψ)0),j=i,v,

    where Bi(ϕ)=Snj=10βj(a)ϕij(a)da and Bv(ϕ)=pϕS. We further define another nonlinear operator

    FS(ψ)=bpψSBi(ψi)+0ϵ(a)ψv(a)da.

    If we set u=(S,(0i),(0v))TZ, A=diag(μ,Ai,Av), and F=(Fs,Fi,Fv), (5) can be rewritten as the following abstract Cauchy problem

    du(t)dt=Au(t)+F(u(t)),u(0)=u0Ω. (9)

    Proposition 2.1. There exists a uniquely determined semiflow {U(t)}t0 on Z0+ such that, for each u=(S(t),(0i(t,)),(0v(t,)))Z0+, there exists a unique continuous map UC(R+,Z0+) which is an integral solution of the Cauchy problem (9), that is, for all t0,

    U(t)u=u0+At0U(s)uds+t0F(U(s)u)ds. (10)

    Proof. By the definition of A and equations (7) and (8), A is dense in part of X0 (see Page 1117, , [22]), and the resolvent operator is bounded. From Proposition 3.2 in, [23], we need only to verify that F satisfies Lipschitz condition. Denote

    xk=(ψSk,(0ψik),(0ψvk))TZ,ˉxk=(ˉψSk,(0ˉψik),(0ˉψvk))TZ,

    and

    LSk=max{pk+pk0ϵk(a)da+bkμknj=1β+kj,bkμknj=1β+kj}.

    By calculation, we have

    |FSk(xk)FSk(ˉxk)|=|pk(ψSkˉψSk)+ψSknj=10βkj(a)ψij(a)daˉψSknj=10βkj(a)ψij(a)da+0ϵk(a)dapk(ψSkˉψSk)|pk|ψSkˉψSk|+nj=10βkj(a)ψij(a)da|ψSkˉψSk|+ψSknj=10βkj(a)|ψij(a)ˉψij(a)|da+p0ϵk(a)da|ψSkˉψSk)|pk|ψSkˉψSk|+bkμknj=1β+kj|ψSkˉψSk|+bkμknj=1β+kjψijˉψijL1+pk0ϵk(a)da|ψSkˉψSk)|LSkxˉx. (11)

    Similarly, we have Flk(xk)Flk(ˉx)Llkxˉx,l=i,v, where Lik=bkμknj=1β+kj, and Lvk=pk. Therefore, F(x)F(ˉx)nk=1Fk(xk)F(ˉxk)Lxˉx, where L=max{LSk,Lik,Lvk}.

    In order to prove the positivity of the solution of (5), we first rewrite the operator Av and the nonlinear function Fvk as follows:

    Av(0ψ)=(0Avψ)=(0ddaψμψ)

    and

    Fv(0ψ)=(pS0ϵ(a)ψ(a)da0).

    Denote A=diag(μ,Ai,Av), and F=(FS,Fi,Fv). Then system (9) can be written as

    du(t)dt=Au(t)+F(u(t)),u(0)=u0. (12)

    It is obvious that eAtu0Ω+ if u0Ω+, where Ω is the positive cone of Ω. Then we need to show that

    t0eA(ts)Fk(Ω+)dsΩ+.

    For any ψlkR and ϕlkΩ+, it follows from the definitions of A and F that

    ψ1+ψ2+ψ3=t0eμ(ts)FS(ϕ(s))ds+t0eμ(ts)tsγ(a)daFi(ϕ(s))ds+t0eμ(ts)Fv(ϕ(s))dst0bkeμ(ts)ds=bkμk(1eμkt)bkμk. (13)

    On the other hand, choose a κkR+ and redefine the operator in (12) as follows: Aκk=diag((μk+κk),Aiκk,Avκk), where

    Aiκk(0ψ)=(0ddaψ(μk+γk(a)+κk)ψ),

    and

    Avκk(0ψ)=(0ddaψ(μk+κk)ψ).

    The nonlinear functions in (12) are defined as Flκk(ϕ)=Flk+κkϕk(l=S,i,v) for any ϕZ. Hence, we have

    t0e(μk+κk)(ts)FSκk(ϕk(s))ds=t0e(μk+κk)(ts)[bkpkϕSk(s)ϕSk(s)nj=10βkj(a)ϕik(t,a)da+t0ϵk(a)ϕvk(a)da+κkϕSk]dst0e(μk+κk)(ts)[bk+(κkpknk=1β+kj)ϕij)]ϕSk(s)ds, (14)
    t0e(μk+κk)(ts)es0γk(a)daFiκk(ϕk(s))ds=t0e(μk+κk)(ts)[ϕSk(s)nj=10βkj(a)ϕij(t,a)da+κkϕik]dst0e(μk+κk)(ts)[ϕSk(s)ε0+κk]ϕikds, (15)

    and

    t0e(μk+κk)(ts)Fvκk(x)ds=t0e(μk+κk)(ts)[pkϕSk(s)0ϵk(a)ϕvk(s,a)da+κϕvk]dst0e(μk+κk)(ts)[pkϕSk(s)+(κkϵ+k)ϕvk]ds. (16)

    If we choose κk>max{pk+nj=1β+kjϕij,ϵ+k}, it follows from (14)-(16) that

    t0eAκk(ts)Fκk(ϕ(s))ds>0,ifϕ>0.

    From what has been discussed above, we have the following result.

    Proposition 2.2. If Assumption 1.1 holds, system (5) has a unique positive solution in Ω.

    In this section, we show the computation process of the basic reproduction number R0, which is the average number of secondary cases produced by a classical infected individual during its infectious period in a fully susceptible population. Many literatures have given different methods to solve this problem. In this paper, it follows from the renewal process mentioned in Diekman et al in [24] that its value is determined by a next generation operator. Note that E0=(ˆS0,0,0,0,ˆv0(a)) is the disease-free equilibrium of system (5) where ˆS0=(S10,S02,,S0n) and ˆv0(a)=(v01(a),v02(a),,v0n(a)) with S0k=bkμk+pk(1K1k),v0k(a)=pkS0kπ1k(a), and π1k(a)=ea0(μk+ϵk(s))ds, K1k=0ϵk(a)π1k(a)da. Linearizing system (5) at the disease-free equilibrium E0, the subsystem (5) can be rewritten as

    i(t,a)t+i(t,a)a=(μ+γ(a))i(t,a),i(t,0)=S0Λ(i(t,)), (17)

    where

    Λ(i(t,))=diagjN(nk=10βjk(a)ik(t,a)da),

    and

    S0=diag(S01,S02,,S0n).

    Let B:D(B)XX be a linear operator defined by

    B(0ϕ(a))=(ϕ(0)ddaϕ(a){μ+γ(a)}ϕ(a)),D(B)={ϕX:ϕis absolutely continuous, ϕL1(R+)}, (18)

    where μ and γ are defined in (6). Based on the above definition, (7) can be rewritten as the following linear Cauchy problem in Z0:

    ddtI(t)=BI(t)+S0ΛI(t),I(0)=I0X, (19)

    Let u(t)=etB be the C0 semigroup generated by the generator B. By the variation of constants formula, we have

    I(t)=u(t)I0+t0u(ts)S0ΛI(s)ds.

    Mapping S0Λ on both sides of the above equation yields

    v(t)=f(t)+t0Ψ(s)v(ts)ds, (20)

    where v(t)=S0ΛI denotes the density of newly infectives in the linear invasion phase, f(t)=S0Λu(t)I0 and Ψ(s)=ΛS0u(s). Then the next generation operator is defined by

    K=0Ψ(s)ds=Λ(S0B)1,

    where we used the relation (zB)1=0ezsV(s)ds, for zρ(B)(ρ(B) denotes the resolvent set of B) and 0ρ(B). In fact, the next generation operator is calculated as follows:

    K=(K1,K2,,Kn)T, (21)

    where

    Kj=nk=1S0k0βjk(a)πk(a)da,j=1,2,,n. (22)

    Based on Diekmann et al [24], the basic reproduction number R0=r(K) is the spectral radius of the next generation operator K, where r(A) denotes the spectral radius of a bounded operator A. It follows from Inaba [25] that Malthusian parameter or asymptotic growth rate of infectives is positive if R0>1, otherwise it is negative.

    In this section, we focus on the existence of the endemic equilibrium E of system (5). It follows from Section 2 that equilibria of system (5) satisfy Au+F(u)=0. Actually, it satisfies the following equations

    0=bk(μk+pk)SkSkλk+0ϵk(a)vk(a)da,dik(a)da=(μk+γk(a))ik(a),ik(0)=Skλk,λk=nj=10βkj(a)ik(a)da,dvk(a)da=(μk+ϵk(a))vk(a),vk(0)=pkSk. (23)

    From the last two equations of (23), we have

    vk(a)=pkSkπ1k(a),π1k(a)=ea0[μk+ϵk(s)]ds. (24)

    Substituting (24) into the first equation of (23) yields

    Sk=bkμk+pk(1K1k)+λk. (25)

    It follows from the second and the third equations of (23) that

    ik(a)=ik(0)πk(a)=Skλkπk(a),πk(a)=ea0[μk+γk(s)]ds.

    Note that

    λk=nj=10βkj(a)ij(a)da=nj=1ij(0)Kkj=nj=1bjλjμj+pj(1K1j)+λjKkj, (26)

    where Kkj=0βkj(a)πj(a)da. Hence, we can define a nonlinear operator

    H(ϕ):=(H1(ϕ),H2(ϕ),,Hn(ϕ))TX,ϕR, (27)

    where

    Hk(ϕ)=nj=1bjϕjμj+pj(1K1j)+ϕjKkj.

    In fact, it follows from (26) that the endemic equilibrium of (23) is a positively nontrivial fixed point of the operator H. Note that the Fréchet derivative of H at ϕ=0 is given by

    Hk[0]=limh0Hk[h]Hk[0]h=limh0nj=1hbjKkjh(μj+pj(1K1j)+h)=limh0nj=1bjKkjμj+pj(1K1j)+h=Kk.

    Let

    H[0]=(ˆH1,ˆH2,,ˆHn),

    where

    ˆHk=nj=1bjμj+pj(1K1j)Kkj=nj=1S0jKkj=Kk,k=1,2,,n.

    Consequently, H[0] is equal to the next generation operator K defined by (21).

    Next, we show that R0 determines the existence of the positive fixed point of operator H. Under Assumption 1.1, the following lemma holds.

    Lemma 4.1. Let K be defined by (21). We have

    (a) K is compact.

    (b)K is nonsupporting.

    Proof. Assume that B0 is an arbitrary bounded subset of R. Then there exists a positive constant c0 such that ϕc0 for all ϕB0. Note that

    K(ϕ)=nj=1|Kj(ϕ)|nj=1nk=1S0k0βjk(a)|ϕk(a)|danj=1nk=1S0kβ+jk0|ϕk(a)|da=nj=1nk=1S0kβ+jkϕkL1. (28)

    (28) implies that the operator K is bounded. It follows from Fréchet-Kolmogorov Theorem [31] that the operator K is compact. It is obvious that K is nonsupporting under (ⅲ) or (ⅲ)' of Assumption 1.1.

    Lemma 4.1, together with the monotonicity of the operator H with respect to ϕ manifests that the following lemma holds.

    Lemma 4.2. Let H be defined (27). H is compact and H(R+) is bounded.

    Employing Theorem 4.11 in [26] (Krasnoselskii fixed theorem) and Krein-Rutman Theorem in [27], Lemma 4.2 implies that r(K) is the uqiue eigenvalue of the operator K associated with a positive eigenvector and there is no eigenvector of K associated with eigenvalue 1. As a consequence of Corollary 5.2 in [15], the following result is immediate.

    Proposition 4.1. If R0>1, then H has at least one nontrivial fixed point in Z0+.

    Corollary 4.1. If R0>1, then system (5) has at least one positive endemic equilibrium E=(S,0,i,0,v)Z0+, where S=(S1,S2,,Sn),i=(i1,i2,,in),v=(v1,v2,,vn).

    In order to determine the uniqueness of the solution of system (23), we define two operators by (ⅱ) and (ⅲ) of Assumption 1.1 as follows:

    H+k(ϕ)=nj=1bjβ+kjϕjμj+pj(1K1j)+ϕj0πj(a)da,kN,

    and for a small positive value δ

    Hk(ϕ)=nj=1bjε0ϕjμj+pj(1K1j)+ϕjaβ+δaβδπj(a)da,kN.

    For convenience, define

    H+(ϕ)=diag(H+1(ϕ),H+2(ϕ),,H+n(ϕ)),

    and

    H(ϕ)=diag(H1(ϕ),H2(ϕ),,Hn(ϕ)).

    It is obvious that 0H(ϕ)eH(ϕ)eH+(ϕ)e, where e=(1,1,,1)T.

    Theorem 4.3. If R0>1, then the operator H defined in (27) has at most one nontrivial fixed point in Z0+.

    Proof. By Proposition 4.1, we assume that there are two different nontrivial fixed points in R+, denoted by ϕ and ˆϕ. Borrowing the definitions of H and H+, we have

    ϕ=H(ϕ)H(ϕ)=H(ϕ)H+(ϕ)H+(ϕ)H(ϕ)H+(ϕ)H(ϕ)=H(ϕ)H+(ϕ)ϕ.

    Hence, there exists a positive constant q=sup{r0,ϕrˆϕ}>0. Suppose 0<q<1, for all ϕR+ and kN, then

    Hk(qϕ)=qHk(ϕ)+ξk(ϕ,q), (29)

    where ξk(ϕ,q)=q(1q)nj=1bjϕj(μj+pj(1K1j)+ϕj)(μj+pj(1K1j)+qϕj)Kkj. It follows from 0<q<1 and (ⅲ) of Assumption 1.1 that ξk is positive for all kN+ and ϕR+. Furthermore,

    H(qϕ)qH(ϕ)+ξ(q,ϕ)e,ξ=diag(ξ1,ξ2,,ξn). (30)

    Inequality (30), together with the monotonicity of H implies that

    ϕ=H(ϕ)qH(ϕ)+ξ(ˆϕ,q)e=qˆϕ+ξ(ˆϕ,q){H+(ˆϕ)}1H+(ˆϕ)eqˆϕ+ξ(ˆϕ,q){H+(ˆϕ)}1H(ˆϕ)=qˆϕ+ξ(ˆϕ,q){H+(ˆϕ)}1ˆϕ. (31)

    This contradicts the definition of q. Therefore, q1 and ϕqˆϕˆϕ. Exchanging the role of ϕ and ˆϕ, we can prove ϕˆϕ. This implies that ϕ=ˆϕ.

    In this section, we will show the relative compactness of the positive orbit {U(t,u0)}t0 defined by (5). This process is spurred by Lemma 19 in [28] and Theorem 2.46 in [29]. To apply them, we define

    ˜ϕk(t,a):={0,t>a,ik(t,a),ta,˜ψk(t,a):={0,t>a,vk(t,a),ta,

    and

    ˜ik(t,a)=ik(t,a)˜ϕk(t,a),˜vk(t,a)=vk(t,a)˜ψk(t,a).

    Then we can divide the solution of semigroup U(t) into two parts:

    V(t)u0=(0,0,˜ϕ(t,),0,˜ψ(t,)) (32)

    and

    W(t)u0=(S(t),0,˜i(t,),0,˜v(t,))T (33)

    where

    ˜ϕ=(˜ϕ1,˜ϕ2,,˜ϕn)T,˜ψ=(˜ψ1,˜ψ2,,˜ψn)T,˜i=(˜i1,˜i2,,˜in)T,˜v=(˜v1,˜v2,,˜vn)T.

    This implies that U(t)u0=V(t)u0+W(t)u0.

    Theorem 5.1. The semiflow U:R+×X0X0 is asymptotically smooth if there are maps V(t),W(t):R+×X0X0 such that U(t)u0=V(t)u0+W(t)u0, and the following statements hold for any bounded closed set Ω that is forward invariant under U:

    (i) For any u0Ω, there exists a function δ:R+×R+R+ such that for any r>0 limt+δ(t,r)=0 with u0Ωr, then V(t,u0)Ωδ(t,r);

    (ii) there exists a tΩ0 such that W(t)(Ω) has a compact closure for each ttΩ.

    Lemma 5.2. There exists a function δ:R+×R+R+ such that for any r>0,

    limt+δ(t,r)=0 (34)

    and

    V(t)u0Ωδ(t,r),u0Z,u0Ωr,t0. (35)

    Proof. Integrating ik and vk equations along the characteristic line ta= const. yields

    ˜ϕ(t,a)={0,t>a,ik0(at)πk(a)πk(at),ta,˜ψ(t,a)={0,t>a,vk0(at)π1k(a)π1k(at),ta

    for all kN. Hence for any u0Y and u0Yr,

    V(t)x0Ω=0+˜ϕ(t,)X+˜ψ(t,)X=nj=1{tij0(at)πj(a)πj(at)da+tvj0(at)π1j(a)π1j(at)da}eμ_tnj=10[ij0(a)+vj0(a)]da=eμ_t{i0X+v0X}eμ_tr

    where δ(t,r)=eμ_tr and μ_=minkN{μk}. Obviously, V(t)u0Ω approaches 0 as t goes to infinity.

    Lemma 5.3. W(t) maps any bounded subsets of Ω into sets with compact closure in Y.

    Proof. It follows from the first equation of (5) that Sk(t) remains in the compact set {ϕRn+|0ϕkbkμk,kN} for all t0. Therefore, we need to show that ˜i and ˜v still remain in pre-compact subsets of Y0 which is independent of u0. Note that

    ˜ik(t,a)={ik(ta,0)πk(a),t>a,0,ta,˜vk(t,a)={vk(ta,0)π1k(a),t>a,0,ta.

    Since for all kN+, 0˜ik(t,a)=ik(ta,0)πk(a)bkμ_2nj=1β+kjbjeμ_a:=Δkeμ_a where Δk=bkμ_2nj=1β+kjbj, and 0˜vk(t,a)bkpkμkeμ_a. It is easy to see that (ⅰ) - (ⅲ) of Theorem B.2 in [29] hold.

    In what follows, we need to show that (iv) of Theorem B.2 in [29] also holds. Assume that h(0,t) without loss of generality. Then

    nj=10|˜ij(t,a+h)˜ij(t,a)|da=nj=1tth|0˜ij(t,a)|da+nj=1th0|˜ij(t,a+h)˜ij(t,a)|danj=1Δjh+nj=1th0˜ij(t,a)|π(h)1|danj=1Δjh+nj=1Δj(th)h=nk=1Δjh(1+th). (36)

    Similarly,

    nj=10|˜vj(t,a+h)˜vj(t,a)|dank=1bjpjμjh(1+th). (37)

    Obviously, both (36) and (48) uniformly converge to 0 as h0 which is independent of u0.

    Lemmas 5.2 and 5.3, together with U(t)u0Z0nk=1bkμk, imply that U(t) has compact closure in Z for u0Ω. It follows from Proposition 3.13 in [32] that the solution orbit is relatively compact and the semiflow U(t) is asymptotically smooth.

    Proposition 5.1. The semiflow U(t) defined in (10) is asymptotically smooth.

    In this section, we establish the uniform persistence of (5) when R0>1. This property guarantees the well-definition of the Lyapunov functionals in Section 7. For some kN, define ρk:ΓR+ and u0=(S0,0,i0(),0,v0())Ω0 by

    ρk(S(t),0,i(t,),0,v(t,))=λk(t)=nj=10βkj(a)ij(t,a)daforu0Ω.

    Let

    Ω0={(S0,0,i0(),0,v0())Ω:ρk(U(t0,u0))>0for somet0R+}.

    Obviously, if u0ΩΩ0, then (S(t),0,i(t,),0,v(t,))E0 as t. Hence, if U has a global compact attractor in Ω0, then it also has a global compact attractor in Ω.

    Assumption 6.1. The support of the initial age-since-infection value ik0(a)L1(R+) lies to the right of the support the infectivity function βkj for all k,jN.

    Proposition 6.1. If R0>1 and Assumption 6.1 hold, then system (5) is uniformly weakly ρ-persistent for some kN.

    Proof. Since R0>1, there exists an ηj0>0 and ϕjR+ for k,jN such that

    nj=1˜S0j(ηj0)ˆKkj(ηj0)ϕj>ϕk, (38)

    where ˜S0k(ηk0)=bkμ+ηk0+pk(1K1k)ηk0(>0) and ^Kkj()=0eλaβkj(a)πk(a)da.

    Suppose that, for any ηk0>0, there exists an u0Ω0 such that

    lim suptρk(U(t,u0))ηk0

    and show a contradiction. Therefore, there exists a t0R+ such that ρk(U(t,u0))ηk0 for tt0 and all kN. Without loss of generality, we shift the time to t0=0. Then λk(t)ηk0 for tt0=0 and kN.

    Next, we show that SkS0k(ηk0):=bkμk+ηk0+pk(1K1k), where Sk=lim inftSk(t). By the Fluctuation Lemma [35], we can pick up a sequence {tn} such that Sk(tn)Sk, dSk(tn)dt0 as n. Then from the first equation of (5), it follows that

    dSk(tn)dtbk(μk+pk)Sk(tn)ηk0Sk(tn)+0εk(a)v(tn,a)da.

    This, combined with (40), gives

    dSk(tn)dtbk(μk+pk)Sk(tn)ηk0Sk(tn)+tn0εk(a)pkSk(tna)π1k(a)da.

    Letting n leads to

    0bk(μ+ϕ)Skηk0Sk+pkSkK1k.

    This implies that SkS0k(ηk0).

    Finally, since SkS0k(ηk0), there exists a t1R+ such that Sk(t)˜S0k(ηk0) for tt1. Again, without loss of generality, we can assume t1=0. Solving ik(t,a) by the characteristic line method yields

    ik(t,a)={bk(ta)πk(a),ta,ik0(at)πk(a)πk(at),t<a, (39)

    where bk(t)=Sk(t)λk(t). Then

    λk(t)=nj=10βkj(a)ij(t,a)danj=1t0βkj(a)Sj(ta)λj(ta)πj(a)danj=1˜Sj(ηj0)t0βkj(a)πj(a)λj(ta)da.

    Taking Laplace transforms on both sides of the above inequality gives

    ^λk(ξ)nj=1˜Sj(ηj0)^Kk(ξ)^λj(ξ).

    This inequality holds for any ξ and ηk0. If we take ξ and ηk0 small enough, then this is a contradiction with (38). This completes the proof.

    Clearly, for all kN, ρk is a continuous function on R+. Proposition 5.1 implies that {U}t0 has a global attractor. From Theorem A.34 in [34], we need to show that for any bounded total orbit h(t+s)=U(s,u(t)) of Ut such that ρk(h(t))>0 for all tR and sR+. For the total trajectory, we have

    ik(t,a)=bk(ta)πk(a),vk(t,a)=pSk(ta)π1k(a)

    for tR and aR+. In order to prove the strongly uniform persistence, the following lemma is helpful.

    Lemma 6.1. Let (S(t),0,i(t,),0,v(t,)) be a solution of (5). Then SkS0k, where Sk=lim suptSk(t) for kN.

    Proof. By Fluctuate Lemma in [35], there exists {tn} such that tn, Sk(tn)Sk, and dSk(tn)dt0 as n. Integrating vk equation in (5) along the characteristic equation ta=const., we have

    vk(t,a)={pkSk(ta)π1k(a),ta,vk0(at)π1k(a)π1k(at),t<a,for allkN. (40)

    Substituting vk into Sk equation yields

    dSk(tn)dt=bk(μk+pk)Sk(tn)Sk(tn)λk(tn)+0εk(a)vk(tn,a)dabk(μk+pk)Sk(tn)+tn0εk(a)pkSk(tna)π1k(a)da+tnεk(a)vk0(atn)π1k(a)π1k(atn)dabk(μk+pk)Sk(tn)+tn0εk(a)pkSk(tna)π1k(a)da+0εk(a+tn)vk0(a)π1k(a+tn)π1k(a)da.

    Applying Fluctuate Lemma, we immediately obtain

    0bk(μk+pk)Sk+pkSkK1k

    or Skbkμk+pk(1K1k)=S0k as required. This completes the proof.

    Lemma 6.2. Let us define Θ(b(t))=nk=1bk(t). Suppose that Assumption 6.1 holds, then Θ(b(t)) for total trajectory h(t) is identically zero on R, or it is strictly positive on R.

    Proof. Suppose that there exists a t1>0 such that bk(t)=0 for all tt1. By the definition of λk, we have

    bk(t)=Sk(t)nj=10βkj(a)ij(t,a)da=Sk(t)nj=10βkj(a)b(ta)πj(a)daS0kˉβ0Θ(b(ta))da=S0kˉβtt10Θ(b(ta))daS0kˉβt0Θ(b(a))da, (41)

    where ˉβ=maxj,kN{β+kj}. Summing k from 1 to n on both sides of (41) yields

    Θ(b(t))t0Θ(b(a))daS0ˉβ,S0ˉβ=nk=1ˉβS0k

    for all t>t1. It follows from Gronwall inequality that Θ(b(t))=0 for all tt1.

    Suppose there doesn't exist a t1 such that Θ(b(t))=0 for all tt1. Thus, there exists a sequence {tm} towards such that Θ(b(tm))>0 for each m. That means that bk(tm)>0 for each m. Moreover, there exists a sequence am such that ik(tm,am)=ik(tmam,0)πk(am)>0 for each m. In view of the first equation, with the dissipative property of system (5), we obtain

    Sk(t)bk(μk+pk)Sk(t).

    Hence, there exists a positive constant ζ>0 such that Sk(t)>ζ>0 holds for all tR. Let bkm(t)=bk(t+tm) for each n, where tm=tmam. Recalling equation (41), we arrive at

    bkm(t)ζ[nj=1t0βkj(a)bjm(ta)πj(a)da+˜Θkm(t)]ζ[ε0t0Θ(bm(ta))da+˜Θkm(t)], (42)

    where ε0 is defined in (ⅲ) of Assumption 1.1 and

    ˜Θkm(t)=nj=1tβkj(a)ijm0(at)πj(a)πj(at)da.

    Consequently,

    Θ(bm(t))ζ[ε0nt0Θ(bm(a))da+˜Θ(t)],˜Θm(t)=nk=1˜Θkm(t). (43)

    Since ˜Θm(0)=nk=1nj=10βkj(a)ijm0(a)da>0 and ˜Θm(t) is continuous at t=0, it follows from Assumption [29] and Gronwall inequality that Θ(bm(t)) and ˜Θm(t) are positive for sufficiently small t. Furthermore, from Corollary B.6 [29], we conclude that there exists a constant l>0 such that Θ(bm(t))>0 for all t>l. Since Θ(bm(t)) is a time shift of Θ(b(t)) by tm with tm as m, it follows that Θ(b(t))>0 for all tR. This completes the proof.

    Corollary 6.1. Suppose that Assumption 6.1 holds. Then for all kN, bk(t) for the total trajectory h(t) is strictly positive for every tR.

    From Propositions 5.1 and 6.1, together with Corollary 6.1, we apply Theorem 5.2 in [29] to illustrate the ρ strongly uniform persistence of system (5).

    Lemma 6.3. Suppose that R0>1 and the assumption of Corollary 6.1 hold. Then system (5) persists uniformly strongly, in this sense, there exists some ηk0 such that

    lim inftλk(t)ηk0

    for some kN and λk(0)0.

    Proof. From Corollary 6.1, we readily see that infλk(0)>0 for some kN. Applying Theorem A.34 in [34], we conclude that there exists a constant ηk0>0 such that lim inft+ρk(U(t,u0))>ηk0.

    By Lemma 6.3, we present the following theorem to state the uniformly strong persistence of system (5).

    Theorem 6.4. Suppose that R0>1 and Assumption 6.1 hold. There exist some positive constants ηk0>0(kN) such that for all tR and aR+

    lim inftSk(t)ηk0,lim inftik(t,a)ηk0πk(a),lim inftvk(t,a)ηk0π1k(a).

    In this section, we will show the global behavior of the equilibria of system (5). To achieve this goal, we employ a Volterra type functional defined by g(x)=x1lnx in [22], which is positive and attains minimum value 0 at x=1. In what follows, we check this Volterra type functional is well-defined in infinite dimension and make the following assumption.

    Assumption 7.1. For all jN+, Sj0R+, 0|lnhj0(a)|da<+, h=i,v.

    Lemma 7.1. If Assumption 7.1 holds, then 0v0j(a)lnvj(t,a)v0j(a)da is bounded.

    Proof. For t>a,

    |v0jlnvj(t,a)v0j(a)|=|v0j(a)lnvj(t,a)v0j(a)lnv0j(a)||v0j(a)lnvj(t,a)|+|v0j(a)lnv0j(a)|=|pjS0jπ1j(a)lnpjS0j(ta)π1j(a)+|pjS0jπ1j(a)lnpjS0jπ1j(a)|2pjS0jlnpjΛjμjeμja+2pjS0jeμjaμja. (44)

    For ta,

    |v0jlnvj(t,a)v0j(a)||v0j(a)lnvj(t,a)|+|v0j(a)lnv0j(a)|=|pjS0jπ1j(a)lnvj0(at)π1j(t)|+|pjS0jπ1j(a)lnpjS0jπ1j(a)|pjS0j|lnvj0(at)π1j(t)|+pjS0jlnpjΛjμjeμja+2pjS0jeμjaμja. (45)

    It follows from (44) - (45) that

    0|v0j(a)lnvj(t,a)v0j(a)|da=0|v0j(a)lnvj(t,a)v0j(a)lnv0j(a)|dapjS0jlnpjΛjμjt0eμjada+pjS0jt|lnvj0(at)|eμjtda+pjS0jlnpjΛjμj0eμjada+2pjS0j0aeμjada=pjS0jlnpjΛjμj(1eμjt)+pjS0jeμjt0|lnvj0(a)|da+pjS0jμjlnpjΛjμj+2pjS0jμj2pjS0jlnpjΛjμj+pjS0jeμjt0|lnvj0(a)|da+2pjS0jμj. (46)

    Therefore, it follows from Assumption 7.1 that 0v0j(a)lnvj(t,a)v0j(a)da is bounded.

    Theorem 7.2. Let Assumption 7.1 hold. If R0=r(K)<1, the disease-free equilibrium E0 is a global attractor in Ω.

    Proof. For jN, define

    Vj(t)=nk=1KjkS0kg(Sk(t)S0k)+nk=10αjk(a)ik(t,a)da+nk=1Kjk0δk(a)g(vk(t,a)v0k(a))da,

    where αkj(a)=aβkj(s)πj(s)πj(a)ds and δk(a)=aεk(s)v0k(s)da. Lemma 7.1 ensures Vj(t) is well-defined. Then

    αkj(a)=βkj(a)+(μk+ϵk(a))αkj(a),δk(a)=ϵk(a)i0k(a). (47)

    From Lemma 7.1, together with 6.4, Vj(t) is well-defined. Deviating it along the solution of (5) yields

    dVj(t)dt|(5)=nk=1{Kjk(1S0kSk(t))Sk+0αjk(a)ijt(t,a)tda+Kjk0δk(a)vk(t,a)tda}=nk=1[Kjk(1S0kSk(t))(bk(μk+pk)Skik(t,0)+0ϵk(a)vk(t,a)da)]+nk=1[Kjkik(t,0)nj=10βkj(a)ik(t,a)da]+nk=1[Kjk0ϵk(a)(g(vk(t,0)v0k)g(vk(t,a)v0k(a)))da]=nk=1[Kjk(μk+pk(1K1k))(2Sk(t)S0kS0kSk(t))]nk=1[Kjk0ϵk(a)g(vk(t,a)S0kv0k(a)Sk(t))da]+nk=1(S0kKjk1)0βjk(a)ik(t,a)da. (48)

    Note that R0=r(K)<1 implies that nk=1S0kKjk<1. Therefore, Vj(t)0 and it is easy to see that the equality holds if and only if (S(t),0,i(t,),0,v(t,))=(S0,0,0,0,v0()). This implies that the largest positive invariant subset of {u(t)Ω|Vj(t)=0} is the singleton {(S0,0,0,0,v0())}. This shows that the disease-free equilibrium E0 is a global attractor.

    In the following, we give a lemma to show the boundedness of the Lyapunov functional for proving the global attractivity of the endemic equilibrium E.

    Lemma 7.3. If Assumption 7.1 holds, then 0hj(a)lnhj(t,a)hj(a)da (h=i,v) is bounded.

    Proof. Prior to this proof, denote β+j=maxkNess.supaR+βjk(a) for all jN. For t>a, it follows from bj(t)β+jΛ2jμ2j that

    |ij(a)lnij(t,a)ij(a)|=|ij(a)lnij(t,a)ij(a)lnij(a)||ij(a)lnij(t,a)|+|ij(a)lnij(a)|=|ij(0)πj(a)lnbj(ta)πj(a)+|ij(0)πj(a)lnij(0)πj(a)|4(Λjμj)2eμjaβ+jlnβ+jΛjμj+2(Λjμj)2eμjaμja. (49)

    For a>t,

    |ij(a)lnij(t,a)ij(a)|=|ij(a)lnij(t,a)ij(a)lnij(a)||ij(a)lnij(t,a)|+|ij(a)lnij(a)|=|ij(0)πj(a)lnij0(at)πj(a)+|ij(0)πj(a)lnij(a)πj(a)|2(Λjμj)2eμja|lnij0(at)|+2(Λjμj)2eμjaβ+jlnβ+jΛjμj+2(Λjμj)2eμjaμja. (50)

    Then,

    0|ij(a)lnij(t,a)ij(a)|da=0|ij(a)lnij(t,a)ij(a)lnij(a)|2Λ2jμ3jβ+jlnβ+jΛjμjt0eμjada+2(Λjμj)2t|lnij0(at)|eμjtda+2Λ2jμ3jβ+jlnβ+jΛjμj0eμjada+2(Λjμj)2μj0aeμjada=2Λ2jμ3jβ+jlnβ+jΛjμj(1eμjt)+2(Λjμj)20|lnij0(a)|eμjtda+2Λ2jμ3jβ+jlnβ+jΛjμj+2Λ2jμ3j4Λ2jμ3jβ+jlnβ+jΛjμj+2(Λjμj)2eμjt0|lnij0(a)|da+2Λ2jμ3j. (51)

    By the assumption, it follows that 0ij(a)lnij(t,a)ij(a)da is bounded.

    Similarly, 0vj(a)lnvj(t,a)vj(a)da is also bounded.

    Assume that f(t,a)R×L1(R+) is a solution of the following system

    f(t,a)t+f(t,a)a=m(a)f(t,a),f(t,0)=L(t)0η(a)f(t,a)da,f(0,a)=f0(a), (52)

    where m(a),η(a)L1(R+) and L(t)R. Obviously, the nontrivial equilibrium E1 of system (52) satisfies the following equations:

    df(a)da=m(a)f(a),f(0)=L0η(a)f(a)da. (53)

    Define a Lyapunov functional V1(t)=0M(a)g(f(t,a)f(a))da, where M(a)=aβ(s) f(s)ds.

    Lemma 7.4. Suppose that 0|lnf0(a)|da is bounded. There exists a positive value η0>0 such that f(t,a)>η0ea0m(s)ds, then

    dV1(t)dt=0M(a)f(a)[g(f(t,0)f(0))g(f(t,a)f(a))]da, (54)

    where M(a)=aη(s)f(s)da.

    Proof. Note that

    g(f(t,a)f(a))a=a(f(t,a)f(a)1lnf(t,a)f(a))=af(t,a)f(a)alnf(t,a)f(a)=fa(t,a)f(a)f(t,a)fa(a)(f(a))2f(a)f(t,a)fa(t,a)f(a)f(t,a)fa(a)(f(a))2=(1f(a)1f(t,a))(fa(t,a)f(t,a))fa(a)f(a)=(1f(a)1f(t,a))fa(t,a)+(1f(a)1f(t,a))m(a)f(t,a), (55)

    where we denote hl(s,l)=h(s,l)l.

    It follows from the proving process of Lemma 7.3, together the assumption of Lemma 7.4 that V1(t) is well-defined. Deviating it along the solution of (52), we obtain

    dV1(t)dt|(52)=0M(a)g(f(t,a)f(a))tda=0M(a)(1f(a)f(t,a))ft(t,a)f(a)da=0M(a)(1f(a)1f(t,a))(fa(t,a)m(a)f(t,a))da=0M(a)(1f(a)1f(t,a))fa(t,a)da0M(a)m(a)f(t,a)da. (56)

    Observing (55), we have

    dV1(t)dt|(52)=0M(a)g(f(t,a)f(a))ada. (57)

    With the help of integral by parts, we obtain

    dV1(t)dt|(52)=M(a)g(f(t,a)f(a))|0+0Ma(a)g(f(t,a)f(a))da=M(0)g(f(t,0)f(0))0η(a)f(a)g(f(t,a)f(a))da=0η(a)f(a)[g(f(t,0)f(0))g(f(t,a)f(a))]da, (58)

    here we used the fact M(0)=0η(a)f(a)da, and M(a)=η(a)f(a).

    Next, we will give the global attractivity of the endemic equilibrium E.

    Theorem 7.5. Suppose R0>1, (iv) of Assumption 1.1 and Assumption 7.1 hold. Then the endemic equilibrium E is a global attractor in Ω0.

    Proof. Define

    V(t)=nj=1κj{Sjg(Sj(t)Sj)+0αj(a)g(ij(t,a)ij(a))da+0δj(a)g(vj(t,a)vj(a))da},

    where αj(a)=nk=1aβjk(s)ik(s)da and δj(a)=aεj(s)vj(s)ds. κj will be determined later and considered as a weighted coefficient. The well-definition of V(t) follows from Lemma 7.3. From the definitions of αj(a) and δj(a), it follows that

    αj(a)=nk=1βjk(a)ik(a),

    and

    δj(a)=εj(a)vj(a).

    Assisting with Lemma 7.4 and deviating V(t) along the solution of (5) yield

    dV(t)dt|(5)=nj=1κj{(1SjSj(t))Sj(t)+nk=10βjk(a)ik(a)[g(ij(t,0)ij(0))g(ij(t,a)ij(a))]da+0ϵj(a)vj(a)[g(vj(t,0)vj(0))g(vj(t,a)vj(a))]da}=nj=1κj{(1SjSj(t))[(μj+pj)(Sj(t)Sj)(Sj(t)nk=10βjk(a)ik(t,a)daSjnk=10βjk(a)ik(a)da)+0ϵj(a)(vj(t,a)vj(a))da]+nk=10βjk(a)ik(a)[g(ij(t,0)ij(0))g(ij(t,a)ij(a))]da+0ϵj(a)vj(a)[g(vj(t,0)vj(0))g(vj(t,a)vj(a))]da}=nj=1κj{(μk+pk)(2Sk(t)SkSkSk(t))+Sjnk=10βjk(a)ik(a)×[ij(t,0)ij(0)ij(t,a)ij(a)ik(t,a)Sj(t)ik(a)Sj+ik(t,a)ik(a)SjSj(t)]da+0ϵj(a)vj(a)[SjSj(t)+Sj(t)SJ1Sjvj(t,a)Sj(t)vj(a)+lnSjvj(t,a)Sj(t)vj(a)]da}. (59)

    Note that

    Sjnk=10βjk(a)ik(a)ik(t,a)Sj(t)ik(a)Sjda=Sj(t)nk=10βjk(a)ik(t,a)da=ij(t,0)=Sjnk=10βjk(a)ik(a)ij(t,0)ij(0)da. (60)

    Equation (60) implies that

    Sjnk=10βjk(a)ik(a)ik(t,a)Sj(t)ij(0)ik(a)Sjij(t,0)da=Sjnk=10βjk(a)ik(a)da. (61)

    Noting that 0ϵk(a)vk(a)da=pkSk0ϵk(a)π1k(a)da=pkSkK1k, it follows from (60) and (61) that

    dV(t)dt|(5)=nj=1κj{(μj+pj(1K1j))(2Sj(t)SjSjSj(t))Sjnk=10βjk(a)ik(a)[g(SjSj(t))+g(ik(t,a)Sj(t)ij(0)ik(a)Sjij(t,0))]da+Sjnk=10βjk(a)ik(a)[Hk(i(t,a))Hj(i(t,a))]da0ϵj(a)vj(a)g(Sjvj(t,a)Sj(t)vj(a))da}, (62)

    where Hj(i)=ij(t,a)ij(a)lnij(t,a)ij(a). Define Θjk=Sj0βjk(a)ik(a)[Hk(i)Hj(i)]da, (j,k=1,2,,n) and a Laplacian matrix

    Θ=(k1θ1kθ21θn1θ12k2θ2kθn2θ1nθ2nknθnk).

    By Lemma 2.1 in [21], we have that the solution space of the linear system Θκ=0 is 1 and one of its basis is given by

    κ=(κ1,κ2,,κn)T=(c11,c22,,cnn)T,

    where cjj>0(j=1,2,,n) denotes the cofactor of the jth diagonal element of matrix Θ. This implies that nk=1θjkκj=nj=1θkjκk and

    nj=1κjnk=10βjk(a)ik(a)[Hk(i(t,a))Hj(i(t,a))]da=nj=1nk=1κk0βkj(a)ij(a)[Hj(i(t,a))Hk(i(t,a))]da. (63)

    Employing the graph-theoretic approach mentioned in [21], (63) is equal to zero. Therefore, V(t)0. The equality holds if and only if ik(t,a)ik(a)=ij(t,0)ij(0)=ij(t,a)ij(a). This implies that i=ci. It follows from the first equation of (5) with respect to the monotonicity of c that c=1. Hence, the largest invariant set of {u(t)Ω0|V(t)=0} is the singleton E. Combining the relative compactness of the solution orbit (see Lemma 5.3) with the invariance principle (see [Theorem 4.2, [30]]), we see that the endemic equilibrium E is a global attractor in Ω0.

    In this section, we perform some numerical experiments to illustrate our theoretical results. For the experimental operability, we set amax=10 instead of infinity. For simplicity, we assume system (5) describes some sexually transmission diseases, such as Zika, Ebola and genital warts etc, which consist of two groups - male group and female group. As some news reported in [33], human papillomaviruses (HPV) is an effective and safe vaccine to control some sexually transmitted diseases inducing by virus. In order to illustrate system (5), we firstly fix the demographic parameters as follows:

    b1=20.5,b2=40.5,μ1=μ2=0.01.

    Hence the total male population maintains the size N1(t)=2050 and the size of the total female population is N2(t)=4050. It has been reported that nearly half of newly infections are diagnosed as females in age range between 15 to 24. Therefore, we assume that the vaccination rates p1=0.21 for male and p2=0.22 for female. Other parameters are associated with infection age in the form of

    y(x,A,B)=1BAΓ(A)xA1exB

    where Γ(n)=(n1)!, or Γ(z)=0xz1exdx(zN). Obviously, y(x,A,B) satisfies (ⅲ)' of Assumption 1.1. We fix γ(a)=y(a,2,5), ε(a)=y(a,1,1) and verify the transmission rate β(a)=y(a,6,B). If we choose B=9, this implies that the mean of the transmission function is 54 and the variance is 486. It follows from Figure 1 that the disease-free equilibrium E0 is asymptotically stable. Then we decrease B=8 associated with the variance changed as 384. Figure 2 shows that the endemic equilibrium E is asymptotically stable.

    Figure 1.  The solution of (5) with initial conditions Sj0=200,ij0(a)=10,V0=10 and all the parameters except B=9 are enclosed in the text.
    Figure 2.  The solution of (5) with initial conditions Sj0=200,ij0(a)=10,V0=10 and all the parameters except B=8 are enclosed in the text.

    Comparing infected male and female populations in Figure 2, we find that the total infected number for female population is larger than that for male population. However, the first peak time for female population is later than the time for male population. Although the vaccination rate for female designed is higher than such rate for male, the level of infected peak and the total number for female population are still larger than those for male population. Consequently, the government should pay more attentions to female population.

    In this paper, we proposed a multi-group SIVS epidemic model with age-since-infection. We calculated the basic reproduction number R0 by the renewal equation, which is the spectral radius of the next generation operator K. From Theorems 7.2 and 7.5, we see that the global attractivity of system (5) is totally determined by R0. This implies that the basic reproduction number is a sharp threshold determining that the disease prevails or vanishes. Implicit Euler method performed illustrates the theoretical results. Numerical experiment shows that the number of the infected females is larger than the number of the infected male although the vaccination rate for female group is higher than that for male group. The government should pay much more concerns on female group for suppressing sexual diseases prevalence.

    Irreducibility of the transmission matrix βjk,j,kN has been highly influential in analyzing the global stability of equilibria. This assumption is still a basic assumption of epidemics spreading on scale free networks. Therefore, we hope our analysis method proving theoretical results and numerical method can be generalized to investigate the dynamics of some epidemic models on complex networks [36]. Besides, oscillation is one of the important phenomena in diseases transmission. What mechanisms resulting in oscillation has been becoming an increasing trend in investigating epidemic models with age-since-infection [37]. We leave this for our future work.

    The authors are very grateful to the Editor-in-Chief, Professor Yang Kuang, and the anonymous referees for their valuable comments and suggestions, which helped us to improve the presentation of this work significantly.

    This work was supported by the National Natural Science Foundation of China (Nos. 61573016, 11871316), Shanxi Scholarship Council of China (2015-094), Shanxi Scientific Data Sharing Platform for Animal Diseases, and Startup foundation for High-level Personal of Shanxi University.

    The authors declare there is no conflict of interest.



    [1] R. L. Siegel, K. D. Miller, A. Jemal, Cancer Statistics, CA Cancer J. Clin., 67 (2017), 7-30.
    [2] G. Gandaglia, P. Ravi, F. Abdollah, A. E. Abd-El-Barr, A. Becker, I. Popa, et al., Contemporary incidence and mortality rates of kidney cancer in the United States, Can. Urol. Assoc. J., 8 (2014), 247-252.
    [3] D. J. Sanchez, M. C. Simon, Genetic and metabolic hallmarks of clear cell renal cell carcinoma, Biochem. Biophys. Acta Rev. Cancer, 1870 (2018), 23-31. doi: 10.1016/j.bbcan.2018.06.003
    [4] P. Fisel, S. Kruck, S. Winter, J. Bedke, J. Hennenlotter, A. T. Nies, et al., DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome, Clin. Cancer Res., 19 (2013), 5170-5181.
    [5] P. Cairns, Renal cell carcinoma, Cancer Biomarks, 9 (2010), 461-473.
    [6] S. H. Rossi, T. Klatte, J. Usher-Smith, G. D. Stewart, Epidemiology and screening for renal cancer, World J. Urol., 36 (2018), 1341-1353. doi: 10.1007/s00345-018-2286-7
    [7] L. Chen, Y. Luo, G. Wang, K. Qian, G. Qian, C. L. Wu, et al., Prognostic value of a gene signature in clear cell renal cell carcinoma, J. Cell Physiol., 234 (2019), 10324-10335.
    [8] L. Guan, J. Tan, H. Li, X. Jin, Biomarker identification in clear cell renal cell carcinoma based on miRNA-seq and digital gene expression-seq data, Gene, 647 (2018), 205-212. doi: 10.1016/j.gene.2017.12.031
    [9] L. Qu, Z. L. Wang, Q. Chen, Y. M. Li, H. W. He, J. J. Hsieh, et al., Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma, Eur. Urol., 74 (2018), 756-763.
    [10] J. I. Lopez, P. Errarte, A. Erramuzpe, R. Guarch, J. M. Cortes, J. C. Angulo, et al., Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma, Hum. Pathol., 54 (2016), 100-105.
    [11] N. Ahuja, A. R. Sharma, S. B. Baylin, Epigenetic Therapeutics: A New Weapon in the War Against Cancer, Ann. Rev. Med., 67 (2016), 73-89. doi: 10.1146/annurev-med-111314-035900
    [12] P. A. Jones, J. P. Issa, S. Baylin, Targeting the cancer epigenome for therapy, Nat. Rev. Genet., 17 (2016), 630-641. doi: 10.1038/nrg.2016.93
    [13] T. W. Grunt, Interacting Cancer Machineries: Cell Signaling, Lipid Metabolism, and Epigenetics, Trends Endocrinol. Metab., 29 (2018), 86-98.
    [14] A. Nebbioso, F. P. Tambaro, C. Dell'Aversana, L. Altucci, Cancer epigenetics: Moving forward, PLoS Genet., 14 (2018), e1007362.
    [15] M. V. Brock, C. M. Hooker, E. Ota-Machida, Y. Han, M. Guo, S. Ames, et al., DNA methylation markers and early recurrence in stage I lung cancer, N. Eng. J. Med., 358 (2008), 1118-1128.
    [16] S. Shen, G. Wang, Q. Shi, R. Zhang, Y. Zhao, Y. Wei, et al., Seven-CpG-based prognostic signature coupled with gene expression predicts survival of oral squamous cell carcinoma, Clin. Epigenet., 9 (2017), 88.
    [17] M. Gundert, D. Edelmann, A. Benner, L. Jansen, M. Jia, V. Walter, et al., Genome-wide DNA methylation analysis reveals a prognostic classifier for non-metastatic colorectal cancer (ProMCol classifier), Gut, 68 (2019), 101-110.
    [18] D. Capper, D. T. W. Jones, M. Sill, V. Hovestadt, D. Schrimpf, D. Sturm, et al., DNA methylation-based classification of central nervous system tumours, Nature, 555 (2018), 469-474.
    [19] A. Colaprico, T. C. Silva, C. Olsen, L. Garofano, C. Cava, D. Garolini, et al., TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data, Nucleic Acids Res., 44 (2016), e71.
    [20] I. Merelli, P. Lio, L. Milanesi, NuChart: an R package to study gene spatial neighbourhoods with multi-omics annotations, PLoS One, 8 (2013), e75146.
    [21] S. Engebretsen, J. Bohlin, Statistical predictions with glmnet, Clin. Epigenet., 11 (2019), 123.
    [22] R. Pidsley, Y. W. CC, M. Volta, K. Lunnon, J. Mill, L. C. Schalkwyk, A data-driven approach to preprocessing Illumina 450K methylation array data, BMC Genom., 14 (2013), 293.
    [23] M. J. Aryee, A. E. Jaffe, H. Corrada-Bravo, C. Ladd-Acosta, A. P. Feinberg, K. D. Hansen, et al., Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays, Bioinformatics, 30 (2014), 1363-1369.
    [24] X. Robin, N. Turck, A. Hainard, N. Tiberti, F. Lisacek, J. C. Sanchez, et al., pROC: an open-source package for R and S+ to analyze and compare ROC curves, BMC Bioinf., 12 (2011), 77.
    [25] G. De Angelis, R. De Angelis, L. Frova, A. Verdecchia, MIAMOD: a computer package to estimate chronic disease morbidity using mortality and survival data, Comput. Methods Programs Biomed., 44 (1994), 99-107. doi: 10.1016/0169-2607(94)90091-4
    [26] S. Hanzelmann, R. Castelo, J. Guinney, GSVA: gene set variation analysis for microarray and RNA-seq data, BMC Bioinf., 14 (2013), 7.
    [27] X. Liu, J. Wen, C. Li, H. Wang, J. Wang, H. Zou, High-Yield Methylation Markers for Stool-Based Detection of Colorectal Cancer, Dig. Dis. Sci., 65 (2020), 1710-1719. doi: 10.1007/s10620-019-05908-9
    [28] H. Liao, J. L. Kang, W. Y. Jiang, C. Deng, J. Yuan, R. Shuai, Delivery of Constitutively Active Mutant MKK6(E) With TAT-OSBP Induces Apoptosis in Human Ovarian Carcinoma HO8910 Cells, Int. J. Gynecol. Cancer, 25 (2015), 1548-1556. doi: 10.1097/IGC.0000000000000538
    [29] C. H. Hsing, H. C. Cheng, Y. H. Hsu, C. H. Chan, C. H. Yeh, C. F. Li, et al., Upregulated IL-19 in breast cancer promotes tumor progression and affects clinical outcome, Clin. Cancer Res., 18 (2012), 713-725.
    [30] J. Y. Wang, Y. Zhu, C. F. Wang, S. L. Zhang, B. Dai, D. W. Ye, A nomogram to predict Gleason sum upgrading of clinically diagnosed localized prostate cancer among Chinese patients, Chin. J. Cancer, 33 (2014), 241-248. doi: 10.5732/cjc.013.10137
    [31] C. K. Lee, R. J. Simes, C. Brown, S. Lord, U. Wagner, M. Plante, et al., Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer, Br. J. Cancer, 105 (2011), 1144-1150.
    [32] S. Taskin, Y. E. Sukur, B. Varli, K. Koyuncu, M. M. Seval, C. Ates, et al., Nomogram with potential clinical use to predict lymph node metastasis in endometrial cancer patients diagnosed incidentally by postoperative pathological assessment, Arch. Gynecol. Obstet., 296 (2017), 803-809.
    [33] S. P. Connell, M. Hanna, F. McCarthy, R. Hurst, M. Webb, H. Curley, et al., A Four-Group Urine Risk Classifier for Predicting Outcome in Prostate Cancer Patients, BJU Int., 2019.
    [34] Y. Zhang, Z. Li, M. Chen, H. Chen, Q. Zhong, L. Liang, et al., Identification of a New Eight-Long Noncoding RNA Molecular Signature for Breast Cancer Survival Prediction, DNA Cell Biol., 38 (2019), 1529-1539.
    [35] Z. Liu, M. Li, Q. Hua, Y. Li, G. Wang, Identification of an eight-lncRNA prognostic model for breast cancer using WGCNA network analysis and a Coxproportional hazards model based on L1-penalized estimation, Int. J. Mol. Med., 44 (2019), 1333-1343.
    [36] Q. Du, Y. Wang, S. Guan, C. Hu, M. Li, L. Zhou, et al., The diagnostic nomogram of platelet-based score models for hepatic alveolar echinococcosis and atypical liver cancer, Sci. Rep., 9 (2019), 19403.
    [37] S. M. Kim, Y. Kim, K. Jeong, H. Jeong, J. Kim, Logistic LASSO regression for the diagnosis of breast cancer using clinical demographic data and the BI-RADS lexicon for ultrasonography, Ultrasonography, 37 (2018), 36-42. doi: 10.14366/usg.16045
  • mbe-18-06-424-Supplementary.pdf
  • This article has been cited by:

    1. Wei Lv, Hanfei He, Kezan Li, Robust optimal control of a network-based SIVS epidemic model with time delay, 2022, 161, 09600779, 112378, 10.1016/j.chaos.2022.112378
    2. Jing Yang, Shaojuan Ma, Juan Ma, Jinhua Ran, Xinyu Bai, Stochastic Analysis for the Dual Virus Parallel Transmission Model with Immunity Delay, 2024, 1557-8666, 10.1089/cmb.2024.0662
  • Reader Comments
  • © 2021 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(3327) PDF downloads(91) Cited by(3)

Figures and Tables

Figures(8)  /  Tables(2)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog